<code id='E94115992C'></code><style id='E94115992C'></style>
    • <acronym id='E94115992C'></acronym>
      <center id='E94115992C'><center id='E94115992C'><tfoot id='E94115992C'></tfoot></center><abbr id='E94115992C'><dir id='E94115992C'><tfoot id='E94115992C'></tfoot><noframes id='E94115992C'>

    • <optgroup id='E94115992C'><strike id='E94115992C'><sup id='E94115992C'></sup></strike><code id='E94115992C'></code></optgroup>
        1. <b id='E94115992C'><label id='E94115992C'><select id='E94115992C'><dt id='E94115992C'><span id='E94115992C'></span></dt></select></label></b><u id='E94115992C'></u>
          <i id='E94115992C'><strike id='E94115992C'><tt id='E94115992C'><pre id='E94115992C'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:78
          Adam's take main illustration
          Molly Ferguson/STAT

          Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

          In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

          advertisement

          This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Big Tobacco's 'harm reduction': Is it for real, or a sham?
          Big Tobacco's 'harm reduction': Is it for real, or a sham?

          TOLGAAKMEN/AFP/GettyImagesThisyearcouldshapeuptobeahistoriconefortobaccocontrol—oroneinwhichBigTobac

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          NVIDIA and Google execs on the future of AI and drug discovery

          STAT'sCaseyRoss(left)andKimberlyPowell,NVIDIA'svicepresidentforhealthcareattheSTATBreakthroughSummit